Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lyell Immunopharma, Inc. (Nasdaq: LYEL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Lyell is a late-stage clinical company developing next-generation CAR T-cell therapies for cancer, and its filings give structured insight into how it reports clinical, financial, and corporate developments.
Among the key documents are Current Reports on Form 8‑K, where Lyell furnishes press releases on quarterly financial results and business highlights, including updates on pivotal trials of rondecabtagene autoleucel (ronde‑cel/LYL314) in relapsed and/or refractory large B-cell lymphoma and progress in its broader CAR T-cell pipeline. Other 8‑K filings describe material agreements, such as the Exclusive License Agreement granting Lyell rights to the GCC‑targeted CAR T-cell product candidate LYL273, and a Securities Purchase Agreement for a private placement of common stock and potential pre‑funded warrants to fund pivotal-stage trials.
Filings also detail unregistered sales of equity securities related to private placements, milestone share issuances following an acquisition, and equity consideration under licensing arrangements. Additional 8‑K items cover changes in key officers, including appointments and resignations in financial leadership roles, providing context on corporate governance and management structure.
On Stock Titan, these filings are complemented by AI-powered tools that can help summarize lengthy documents, highlight items such as financing terms, licensing economics, and clinical milestone triggers, and surface relevant sections across multiple reports. Users interested in LYEL can review Forms 8‑K and other periodic reports as they become available to track how Lyell discloses clinical progress, capital structure changes, and significant agreements connected to its CAR T-cell programs.
Lyell Immunopharma’s President and CEO, Lynn Seely, reported an open‑market sale of company stock. On February 11, 2026, she sold 7,455 shares of common stock at a weighted average price of $23.39 per share. According to the filing, these shares were automatically sold to satisfy tax withholding obligations arising from the settlement of performance-based vested restricted stock units, rather than a discretionary sale of investment holdings. After this transaction, Seely directly beneficially owned 74,266 shares of Lyell Immunopharma common stock.
Lyell Immunopharma's Chief Operating Officer Stephen J. Hill reported an open-market sale of 1,236 shares of common stock on February 11, 2026. The shares were automatically sold to cover tax withholding obligations from the settlement of performance-based vested restricted stock units.
The sale was executed at a weighted average price of $23.39 per share, with individual trade prices ranging from $23.3939 to $24.7850 per share. Following this transaction, Hill directly beneficially owns 17,795 shares of Lyell Immunopharma common stock.
Lyell Immunopharma’s Chief Scientific Officer, Gary K. Lee, reported an open-market sale of 1,671 shares of common stock on February 11, 2026. The shares were automatically sold to cover tax withholding from performance-based vested restricted stock units.
The weighted average sale price was $23.39 per share, within a disclosed range of $23.3939 to $24.6305. After this tax-related sale, Lee directly beneficially owns 16,938 shares of Lyell Immunopharma common stock.
Lyell Immunopharma Chief Operating Officer Stephen J. Hill reported several equity transactions. He received 4,000 shares of common stock on February 9, 2026 from performance-based restricted stock units that vested after meeting certified performance criteria. On February 10, 2026 he was granted an option for 65,000 shares of common stock at an exercise price of $23.71 per share, with vesting beginning six months after February 9, 2026 and continuing monthly until fully vested, contingent on continued service. Also on February 10, he sold 109 shares at $23.12 per share to cover tax withholding from vested restricted stock units, leaving him with 19,031 common shares held directly.
Lyell Immunopharma’s Chief Scientific Officer Gary K. Lee reported several equity transactions. On February 9, 2026, he acquired 4,000 shares of common stock at $0 from performance-based restricted stock units, bringing his direct holdings to 18,756 shares.
On February 10, 2026, Lee was granted an option for 50,000 shares of common stock at an exercise price of $23.71, vesting over time through February 9, 2036. That same day, 147 shares were sold at $23.12 to cover tax withholding from vested restricted stock units, leaving him with 18,609 common shares held directly.
Lyell Immunopharma President and CEO Lynn Seely reported several equity compensation transactions. On February 9, 2026, Seely acquired 20,000 shares of common stock at $0, issued upon achievement of performance-based restricted stock unit criteria, bringing direct holdings to 82,159 shares.
On February 10, 2026, Seely sold 438 common shares at $23.12 per share, described as an automatic sale to cover tax withholding from vested restricted stock units, leaving 81,721 shares held directly. Also on February 10, Seely received a new option grant for 155,000 shares at an exercise price of $23.71 per share, vesting 12.5% six months after February 9, 2026 and then monthly in equal installments until fully vested, contingent on continued service.
Lyell Immunopharma General Counsel Mark A. Meltz received a grant of options to purchase 50,000 shares of common stock on February 10, 2026. The options have an exercise price of $23.71 per share and are held directly by him.
According to the vesting schedule, 12.5% of the shares subject to the option become vested and exercisable six months after February 9, 2026. The remaining shares vest in equal monthly installments of 1/48 of the total, so the option becomes fully vested over four years, contingent on his continued service.
Lyell Immunopharma VP, Corporate Controller Veronica Sanchez Bulis reported an equity grant and a small share sale. On
The RSUs vest over time: 12.5% on
Lyell Immunopharma Chief Medical Officer David Shook received a grant of stock options. On February 10, 2026, he was awarded an option to buy 50,000 shares of Lyell Immunopharma common stock at an exercise price of
The option vests over time: 12.5% of the shares become exercisable six months after February 9, 2026, and the remaining shares vest in equal monthly installments until fully vested, as long as he continues providing service. Following this grant, he also directly held 21,900 shares of common stock.
Lyell Immunopharma VP Veronica Sanchez Bulis reported two sales of company stock. On 12/24/2025 she sold 1,136 shares of common stock at a weighted average price of $38.67 per share, in a series of trades where individual prices ranged from $38.6643 to $38.6751 per share. On 12/30/2025 she sold an additional 936 shares at $32.32 per share. After these transactions, she held 7,141 shares of Lyell Immunopharma common stock directly.
FAQ
What is the current stock price of Lyell Immunopharma (LYEL)?
What is the market cap of Lyell Immunopharma (LYEL)?
